{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:58:29Z","timestamp":1794340709283,"version":"4.9.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Overweight and obesity are major global health issues, increasing disease risk and straining healthcare systems. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for weight loss but cause gastrointestinal side effects, affecting adherence. Research often focuses on diabetics, leaving a gap in understanding their effects on non-diabetic individuals with overweight or obesity. This systematic review and dose-response network meta-analysis addresses this gap, analyzing gastrointestinal adverse events from GLP-1 RAs in non-diabetic subjects with overweight or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated available evidence by searching PubMed and EMBASE databases, according to specific inclusion and exclusion eligibility criteria to evaluate gastrointestinal adverse events associated with GLP-1 RAs in non-diabetic individuals with overweight or obesity. Quality assessment of included studies was conducted using Cochrane Collaboration\u2019s tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine articles were included in the review showing a total number of 33,354 individuals. Nausea, vomiting, diarrhea, and constipation were the most common gastrointestinal adverse effects. All evaluated GLP-1 RAs led to a significant increase in nausea risk, with orforglipron showing the highest risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. Additionally, liraglutide, orforglipron, semaglutide, and tirzepatide were associated with increased vomiting risk, while cagrilinitide and exenatide showed no significant increase. Exenatide, cagrilinitide, orforglipron were not associated with diarrhea risk. Finally, semaglutide and liraglutide were associated to increased constipation risk, while cagrilinitide and exenatide showed no significant increase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 RAs showed several adverse gastrointestinal effects in non-diabetic patients with overweight or obesity. Understanding the different risk profiles of GLP-1 RAs helps clinicians make informed treatment decisions by balancing therapeutic benefits with potential side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41366-025-01859-6","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:27:37Z","timestamp":1755098857000},"page":"1946-1957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-271X","authenticated-orcid":false,"given":"Abdulrahman","family":"Ismaiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Guido Maria","family":"Scarlata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Boitos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel-Corneliu","family":"Leucuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan-Lucian","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahlah","family":"Al Srouji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Abenavoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan L.","family":"Dumitrascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"1859_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(22)00073-0","volume":"10","author":"AM Tsur","year":"2022","unstructured":"Tsur AM, Twig G. The actual burden of obesity-accounting for multimorbidity. Lancet Diab Endocrinol. 2022;10:233\u2013234.","journal-title":"Lancet Diab Endocrinol"},{"key":"1859_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2023.03.008","volume":"92","author":"X Zhang","year":"2023","unstructured":"Zhang X, Ha S, Lau HC, Yu J. Excess body weight: novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023;92:16\u201327.","journal-title":"Semin Cancer Biol"},{"key":"1859_CR3","doi-asserted-by":"publisher","unstructured":"Gaskin CJ, Cooper K, Stephens LD, Peeters A, Salmon J, Porter J. Clinical practice guidelines for the management of overweight and obesity published internationally: a scoping review. Obes Rev. 2024:e13700. https:\/\/doi.org\/10.1111\/obr.13700.","DOI":"10.1111\/obr.13700"},{"key":"1859_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/healthcare11030433","volume":"11","author":"M Kosmalski","year":"2023","unstructured":"Kosmalski M, Deska K, B\u0105k B, R\u00f3\u017cycka-Kosmalska M, Pietras T. Pharmacological support for the treatment of obesity-present and future. Healthcare. 2023;11:433.","journal-title":"Healthcare"},{"key":"1859_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799","volume":"14","author":"JY Wang","year":"2023","unstructured":"Wang JY, Wang QW, Yang XY, Yang W, Li DR, Jin JY, et al. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol. 2023;14:1085799.","journal-title":"Front Endocrinol"},{"key":"1859_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/jcm12010145","volume":"12","author":"JJ Gorgojo-Mart\u00ednez","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, Castro A, Cebri\u00e1n-Cuenca A, de Torres-S\u00e1nchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12:145.","journal-title":"J Clin Med"},{"key":"1859_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.975880","volume":"14","author":"X Tan","year":"2023","unstructured":"Tan X, Pan X, Wu X, Zheng S, Chen Y, Liu D, et al. Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus. Front Pharm. 2023;14:975880.","journal-title":"Front Pharm"},{"key":"1859_CR8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1859_CR9","unstructured":"Higgins J, Sally G. Cochrane Handbook for Systematic Reviews of Interventions. 2011. Available online at: http:\/\/handbook-5-1.cochrane.org\/ (accessed 24 April 2024)."},{"key":"1859_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106:1\u201340.","journal-title":"J Stat Softw"},{"key":"1859_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12432","volume":"11","author":"M Alba","year":"2021","unstructured":"Alba M, Yee J, Frustaci ME, Samtani MN, Fleck P. Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study. Clin Obes. 2021;11:e12432.","journal-title":"Clin Obes"},{"key":"1859_CR12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606\u20131616.","journal-title":"Lancet"},{"key":"1859_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843\u2013854.","journal-title":"Int J Obes"},{"key":"1859_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40:1310\u20131319.","journal-title":"Int J Obes"},{"key":"1859_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/dc11-0931","volume":"35","author":"J Dushay","year":"2012","unstructured":"Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diab Care. 2012;35:4\u201311.","journal-title":"Diab Care"},{"key":"1859_CR16","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:2670\u20132678.","journal-title":"J Clin Endocrinol Metab"},{"key":"1859_CR17","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736\u20131748.","journal-title":"Lancet"},{"key":"1859_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/jdv.12629","volume":"29","author":"A Faurschou","year":"2015","unstructured":"Faurschou A, Gyldenl\u00f8ve M, Rohde U, Thyssen JP, Zachariae C, Skov L, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients\u2013a randomized placebo-controlled trial. J Eur. Acad Dermatol Venereol. 2015;29:555\u2013559.","journal-title":"Acad Dermatol Venereol"},{"key":"1859_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diab Obes Metab. 2018;20:215\u2013218.","journal-title":"Diab Obes Metab"},{"key":"1859_CR20","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u20132091.","journal-title":"Nat Med"},{"key":"1859_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","volume":"113","author":"H Gudbergsen","year":"2021","unstructured":"Gudbergsen H, Overgaard A, Henriksen M, W\u00e6hrens EE, Bliddal H, Christensen R, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr. 2021;113:314\u2013323.","journal-title":"Am J Clin Nutr"},{"key":"1859_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","volume":"2","author":"H Halawi","year":"2017","unstructured":"Halawi H, Khemani D, Eckert D, O\u2019Neill J, Kadouh H, Grothe K, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2:890\u2013899.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1859_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol. 2017;87:767\u2013774.","journal-title":"Clin Endocrinol"},{"key":"1859_CR24","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/ijo.2014.177","volume":"39","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Lundgren J, Dirksen C, Jensen JE, Pedersen O, Hansen T, et al. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes. 2015;39:834\u2013841.","journal-title":"Int J Obes"},{"key":"1859_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170:451\u2013459.","journal-title":"Eur J Endocrinol"},{"key":"1859_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","volume":"8","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015;8:32.","journal-title":"J Ovarian Res"},{"key":"1859_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3892\/etm.2016.3081","volume":"11","author":"M Jensterle","year":"2016","unstructured":"Jensterle M, Goricar K, Janez A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study. Exp Ther Med. 2016;11:1194\u20131200.","journal-title":"Exp Ther Med"},{"key":"1859_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705\u2013719.","journal-title":"Lancet"},{"key":"1859_CR29","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160\u20132172.","journal-title":"Lancet"},{"key":"1859_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ijo.2013.149","volume":"38","author":"ME Lean","year":"2014","unstructured":"Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, R\u00f6ssner S, et al. NN8022-1807 Investigators. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes. 2014;38:689\u2013697.","journal-title":"Int J Obes"},{"key":"1859_CR31","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384:1719\u20131730.","journal-title":"N Engl J Med"},{"key":"1859_CR32","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/dom.12954","volume":"19","author":"P Lundkvist","year":"2017","unstructured":"Lundkvist P, Pereira MJ, Katsogiannos P, Sj\u00f6str\u00f6m CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1\u2009year. Diab Obes Metab. 2017;19:1276\u20131288.","journal-title":"Diab Obes Metab"},{"key":"1859_CR33","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1097\/CM9.0000000000001712","volume":"134","author":"RL Ma","year":"2021","unstructured":"Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome. Chin Med J. 2021;134:2882\u20132889.","journal-title":"Chin Med J"},{"key":"1859_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EC-16-0113","volume":"6","author":"M Nylander","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Kistorp C, Faber J, Skouby SO. Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocr Connect. 2017;6:89\u201399.","journal-title":"Endocr Connect"},{"key":"1859_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637\u2013649.","journal-title":"Lancet"},{"key":"1859_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"key":"1859_CR37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414\u20131425.","journal-title":"JAMA"},{"key":"1859_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138\u2013150.","journal-title":"JAMA"},{"key":"1859_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179:1\u201311.","journal-title":"Eur J Endocrinol"},{"key":"1859_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/osp4.486","volume":"7","author":"AR Saxena","year":"2021","unstructured":"Saxena AR, Banerjee A, Corbin KD, Parsons SA, Smith SR. Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: a randomized trial. Obes Sci Pr. 2021;7:281\u2013290.","journal-title":"Obes Sci Pr"},{"key":"1859_CR41","doi-asserted-by":"publisher","first-page":"E1314","DOI":"10.1210\/jc.2011-0038","volume":"96","author":"L Sze","year":"2011","unstructured":"Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2011;96:E1314\u2013E1319.","journal-title":"J Clin Endocrinol Metab"},{"key":"1859_CR42","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J van Can","year":"2014","unstructured":"van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes ((Lond)). 2014;38:784\u2013793.","journal-title":"Int J Obes ((Lond))"},{"key":"1859_CR43","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37:1443\u20131451.","journal-title":"Int J Obes"},{"key":"1859_CR44","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial. JAMA. 2021;325:1403\u20131413.","journal-title":"JAMA"},{"key":"1859_CR45","doi-asserted-by":"publisher","unstructured":"Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-02883-1.","DOI":"10.1038\/s41591-024-02883-1"},{"key":"1859_CR46","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877\u2013888.","journal-title":"N Engl J Med"},{"key":"1859_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","volume":"24","author":"S Wharton","year":"2022","unstructured":"Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diab Obes Metab. 2022;24:94\u2013105.","journal-title":"Diab Obes Metab"},{"key":"1859_CR48","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/nu15030556","volume":"15","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qu Z, Lu T, Shao X, Cai M, Dilimulati D, et al. Effects of a dulaglutide plus calorie-restricted diet versus a calorie-restricted diet on visceral fat and metabolic profiles in women with polycystic ovary syndrome: a randomized controlled trial. Nutrients. 2023;15:556.","journal-title":"Nutrients"},{"key":"1859_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.obmed.2017.06.003","volume":"7","author":"S Zheng","year":"2017","unstructured":"Zheng S, Zhang Y, Long T, Lu J, Liu X, Yan J, et al. Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight\/obese PCOS women. Obes Med. 2017;7:15\u201320.","journal-title":"Obes Med"},{"key":"1859_CR50","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.2024.2252","volume":"331","author":"D Mozaffarian","year":"2024","unstructured":"Mozaffarian D. GLP-1 agonists for obesity-a new recipe for success?. JAMA. 2024;331:1007\u20131008.","journal-title":"JAMA"},{"key":"1859_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/230624","volume":"2012","author":"F Sun","year":"2012","unstructured":"Sun F, Yu K, Yang Z, Wu S, Zhang Y, Shi L, et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diab Res. 2012;2012:230624.","journal-title":"Exp Diab Res"},{"key":"1859_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, Chen Y, Zhou X, Liu S, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol. 2023;14:1149328.","journal-title":"Front Endocrinol"},{"key":"1859_CR53","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"key":"1859_CR54","first-page":"935","volume":"49","author":"G Zhuo-yue","year":"2014","unstructured":"Zhuo-yue G, Tian-sheng W, Man-ling M, Suo-di Z. A meta-analysis of GI adverse events of GLP-1 receptor agonists and DPP-4 inhibitors. Chin Pharm J. 2014;49:935\u2013940.","journal-title":"Chin Pharm J"},{"key":"1859_CR55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/dom.14202","volume":"23","author":"CK Rayner","year":"2021","unstructured":"Rayner CK, Wu T, Aroda VR, Whittington C, Kanters S, Guyot P, et al. Gastrointestinal adverse events with insulin glargine\/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: a network meta-analysis. Diab Obes Metab. 2021;23:136\u2013146.","journal-title":"Diab Obes Metab"},{"key":"1859_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/dia.2014.0188","volume":"17","author":"F Sun","year":"2015","unstructured":"Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diab Technol Ther. 2015;17:35\u201342.","journal-title":"Diab Technol Ther"},{"key":"1859_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/11795514231213568","volume":"16","author":"M Wajid","year":"2023","unstructured":"Wajid M, Sattar S, Khalid F, Masood MQ. Efficacy and tolerability of semaglutide in patients with type-2 diabetes mellitus: experience of a tertiary care hospital, Pakistan. Clin Med Insights Endocrinol Diab. 2023;16:11795514231213568.","journal-title":"Clin Med Insights Endocrinol Diab"},{"key":"1859_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DMSO.S348025","volume":"15","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Chen M, Liu L, Chen Z. Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study. Diab Metab Syndr Obes. 2022;15:155\u2013163.","journal-title":"Diab Metab Syndr Obes"},{"key":"1859_CR59","doi-asserted-by":"crossref","unstructured":"Niu C, Zhang J, Bhatta P, Zhu K, Farooq U, Malik S, et al. Exploring gastrointestinal and hepatobiliary adverse events in GLP-1 receptor agonists therapy: a large cohort retrospective study. Gastroenterol. 2024;166:S-283.","DOI":"10.1016\/S0016-5085(24)01134-X"},{"key":"1859_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.","journal-title":"Mol Metab"},{"key":"1859_CR61","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"M Monami","year":"2017","unstructured":"Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diab Obes Metab. 2017;19:1233\u20131241.","journal-title":"Diab Obes Metab"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01859-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01859-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:03:06Z","timestamp":1760608986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-025-01859-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1038\/s41366-025-01859-6","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}